International Assets Investment Management LLC Buys 39,820 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX)

International Assets Investment Management LLC grew its stake in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) by 274.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 54,320 shares of the company’s stock after acquiring an additional 39,820 shares during the period. International Assets Investment Management LLC’s holdings in Anixa Biosciences were worth $2,110,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its position in shares of Anixa Biosciences by 397.7% in the third quarter. Tower Research Capital LLC TRC now owns 15,763 shares of the company’s stock worth $52,000 after purchasing an additional 12,596 shares during the last quarter. LPL Financial LLC increased its position in shares of Anixa Biosciences by 22.9% in the third quarter. LPL Financial LLC now owns 28,138 shares of the company’s stock worth $92,000 after purchasing an additional 5,250 shares during the last quarter. Dakota Wealth Management bought a new position in shares of Anixa Biosciences in the third quarter worth approximately $49,000. Mission Wealth Management LP bought a new position in shares of Anixa Biosciences in the third quarter worth approximately $1,639,000. Finally, Tyler Stone Wealth Management bought a new position in shares of Anixa Biosciences in the second quarter worth approximately $67,000. 29.13% of the stock is currently owned by institutional investors.

Insider Transactions at Anixa Biosciences

In related news, CEO Amit Kumar purchased 30,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were acquired at an average price of $3.22 per share, for a total transaction of $96,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 491,925 shares in the company, valued at approximately $1,583,998.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Anixa Biosciences news, Director Arnold M. Baskies bought 10,000 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were purchased at an average price of $3.63 per share, for a total transaction of $36,300.00. Following the acquisition, the director now owns 110,000 shares in the company, valued at approximately $399,300. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Amit Kumar bought 30,000 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were acquired at an average price of $3.22 per share, for a total transaction of $96,600.00. Following the acquisition, the chief executive officer now owns 491,925 shares in the company, valued at approximately $1,583,998.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 55,009 shares of company stock worth $182,130. Insiders own 22.60% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Anixa Biosciences in a research note on Thursday, March 21st.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock opened at $3.12 on Friday. Anixa Biosciences, Inc. has a 52-week low of $2.75 and a 52-week high of $5.13. The stock has a market capitalization of $99.53 million, a price-to-earnings ratio of -9.18 and a beta of 0.84. The company’s 50 day moving average price is $3.46 and its 200-day moving average price is $3.63.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Tuesday, March 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, equities research analysts forecast that Anixa Biosciences, Inc. will post -0.44 earnings per share for the current fiscal year.

Anixa Biosciences Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.